Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EyePoint's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EyePoint's regulatory disclosures and financial reporting.
Adage Capital Management, L.P. and related parties report a 5.68% beneficial stake in EyePoint, Inc. common stock. They collectively hold 4,700,000 shares with shared voting and dispositive power and no sole authority. The percentage is based on 82,787,220 shares outstanding as of October 30, 2025.
The filing is made on Schedule 13G/A, indicating the position is held in the ordinary course of business and not for the purpose of changing or influencing control of EyePoint. The reporting persons are Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross.
On January 6, 2026, EyePoint, Inc. director Nancy Lurker acquired 75,133 shares of common stock at $0.00 per share upon the vesting and settlement of previously granted restricted stock units. These units were part of an award that vests in three equal annual installments beginning January 6, 2024.
Following this transaction, she directly owned 294,346 shares of EyePoint common stock. An additional 126,889 shares are held indirectly by a family trust for the benefit of her children, for which her spouse is trustee, and she disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. President and CEO Jay S. Duker, who also serves as a director, reported routine equity activity on January 6, 2026 related to previously granted restricted stock units. A block of 20,793 restricted stock units converted into the same number of shares of common stock at an exercise price of $0.00, reflecting vesting of his equity award. To cover taxes on this vesting, 10,054 shares of common stock were withheld by EyePoint at a price of $16.86, and the filing specifies that no shares were sold in the market. After these transactions, Duker directly held 77,752 shares of common stock, and an additional 99,165 shares were reported as indirectly held by a family trust for the benefit of his children, for which he disclaims beneficial ownership.
EyePoint, Inc.’s Chief Financial Officer, Elston George, reported equity compensation activity involving restricted stock units and common shares. On January 6, 2026, 15,285 restricted stock units converted into 15,285 shares of common stock at an exercise price of $0.00, increasing his directly held common shares before withholding to 96,339.
On the same date, 4,487 of those common shares were withheld by the issuer at $16.86 per share to satisfy tax withholding obligations, rather than being sold in the market, leaving 91,852 common shares held directly. An additional 25,000 common shares are reported as held indirectly in a family trust for the benefit of his children, with the trust company as trustee and George disclaiming beneficial ownership of those securities.
EyePoint, Inc. Chief Medical Officer Ribeiro Ramiro reported exercising stock options and selling company shares. On January 5, 2026, Ramiro exercised an option to buy 29,250 shares of common stock at $8.26 per share, increasing his directly held common stock to 42,544 shares. That same day, he reported selling 42,544 shares of common stock at a weighted average price of $17.0957 per share, leaving him with no directly held common stock after the transactions.
Ramiro continues to hold 87,750 stock options following the reported activity. According to the filing, the option vests with 25% on January 3, 2026, with the remaining portion vesting monthly over the next three years, and carries an expiration date of January 3, 2035. The weighted average sale price reflects multiple trades between $16.68 and $17.51.
EyePoint, Inc. filed a current report to let investors know it has released a press release with preliminary cash information as of December 31, 2025 and other corporate updates. The company notes that these figures are preliminary, unaudited and may change once full audited financial statements for the year are completed. The press release is included as Exhibit 99.1, allowing the disclosed preliminary cash position and corporate developments to be incorporated by reference in future securities offerings or other SEC filings.
EyePoint, Inc. Chief Financial Officer Elston George reported multiple equity compensation transactions and related share issuances and tax withholdings in early January 2026. On January 2, 2026, he received 63,000 restricted stock units and a stock option for 126,000 shares, both at an exercise or conversion price of $0.00, with the RSUs vesting in three annual installments beginning January 2, 2027 and the option vesting 25% on January 2, 2027 and the remainder monthly over three years. On January 3 and 5, 2026, previously granted RSUs vested and converted into a total of 34,667 shares of common stock, with 6,324 and 4,403 shares withheld at prices of $17.48 and $17.43 to satisfy tax obligations, and no shares sold into the market. Following these transactions, he directly held 81,054 shares of common stock and derivative awards, and an additional 25,000 shares are held indirectly by a family trust for his children, for which he disclaims beneficial ownership.
EyePoint, Inc. director Reginald J. Sanders reported a grant of stock options. On January 2, 2026, he received 40,000 stock options with an exercise price of $17.48 per share. These options become exercisable on January 2, 2027 and expire on January 2, 2036, and each option corresponds to one share of common stock. Following this grant, Sanders beneficially owns 40,000 derivative securities, held in direct ownership.
EyePoint, Inc. director Nancy Lurker reported equity awards and updated share holdings. On January 2, 2026, she was granted a stock option to buy 40,000 shares of common stock at $17.48, exercisable starting January 2, 2027 and expiring January 2, 2036. On January 5, 2026, 12,666 restricted stock units were converted into the same number of common shares at $0.00 per share, leaving her with 219,213 shares of common stock held directly and 12,667 restricted stock units outstanding. Separately, 126,889 shares of common stock are held indirectly through a family trust for her children, with her spouse as trustee, and she disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. director Duty Stuart reported a grant of stock options in a Form 4 filing. On January 2, 2026, Stuart received a stock option (right to buy) covering 40,000 shares of EyePoint common stock at a conversion or exercise price of $17.48 per share. The option is first exercisable on January 2, 2027 and is scheduled to expire on January 2, 2036. Following this grant, Stuart beneficially owned 40,000 derivative securities related to EyePoint common stock, held in direct ownership form.